The American Lung Association released its 2024 "State of Lung Cancer" report, highlighting a 26% increase in survival and a 15% decrease in incidence, though care disparities across state lines and ...

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

A recent study by a team of researchers at Vanderbilt University found that response to radiation therapy for triple negative ...

Certain chronic conditions that affect the lungs, such as asthma and chronic obstructive pulmonary disease (COPD), can have ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

Gliocidin selectively kills glioblastoma cells by inhibiting nucleotide synthesis, showing potential as a therapeutic option ...

"Not even two weeks later, his lung collapsed the night before my ... the odds and decided it wasn't necessary because with surgery and aggressive treatments, she would be cancer-free and could resume ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

American Lung Association’s ‘State of Lung Cancer’ report reveals stark differences in survival, screening and treatment across states ...